8:41 AM · 28 September 2022

Biogen rallies 50% in premarket on Alzheimer drug trial results

Shares of Biogen, a US biotech company, trade around 50% higher in premarket today. Shares rally following results of an Alzheimer drug (Lecanemab) trial that Biogen developed along with Eisai, Japanese pharmaceutical company. Results showed that the pace of cognitive decline in patients who received Lecanemab dropped by 27% over 18 months compared to patients who received placebo. This is massive as it is the first drug to show effectiveness against Alzheimer in a definitive, large-scale trial. While the company noted that some side effects occurred, it also said that they were rarely severe.

Biogen trades around 50% higher in premarket today. Weekly chart. Source: xStation5

6 November 2026, 7:12 PM

Daily summary: Wall Street rebounds after the sell-off 🔼 US dollar strengthens on solid NFP data, oil prices fall

6 November 2026, 7:00 PM

Vistra shares surge nearly 10% after earnings, driven by strong AI power demand

6 November 2026, 3:27 PM

US Open: Nasdaq rebounds after the largest decline since 19-month 🔼 Lam Research surges 12%

6 November 2026, 11:53 AM

Airbnb surges 12% driven by revenue dynamic at 3-year high

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits